Skip Navigation


PEDS Advance Access originally published online on August 22, 2006
Protein Engineering Design and Selection 2006 19(10):471-478; doi:10.1093/protein/gzl033
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
19/10/471    most recent
gzl033v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (6)
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Silacci, M.
Right arrow Articles by Neri, D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Silacci, M.
Right arrow Articles by Neri, D.
Related Collections
Right arrow 2006
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2006. Published by Oxford University Press. All rights reserved. For Permissions, please e-mail: journals.permissions@oxfordjournals.org

Human monoclonal antibodies to domain C of tenascin-C selectively target solid tumors in vivo

Michela Silacci1, Simon S. Brack1, Nicolas Späth2, Alfred Buck2, Sven Hillinger3, Stephan Arni3, Walter Weder3, Luciano Zardi4 and Dario Neri1,5

1 Institute of Pharmaceutical Sciences, Department of Chemistry and Applied Biosciences, Swiss Federal Institute of Technology (ETH) Zürich Wolfgang-Paulistrasse 10, CH-8093 Zürich 2 PET Center, Division of Nuclear Medicine, University Hospital Zurich CH-8091 Zurich 3 Thoracic Surgery, Department of Surgery, University Hospital Zurich Rämistrasse 100, CH-8091 Zurich, Switzerland 4 Laboratory of Innovative Therapies, Department of Experimental and Clinical Immunology, Advanced Biotechnology Center, Istituto Giannina Gaslini Genoa, Italy

5To whom correspondence should be addressed. E-mail: neri{at}pharma.ethz.ch

We had previously reported that splice isoforms of tenascin-C containing the extra-domain C are virtually absent in normal adult tissues but are highly abundant in high-grade astrocytomas, with a prominent peri-vascular pattern of expression. We now report that the extra-domain C of tenascin-C is strongly expressed in the majority of lung cancers, with a vascular and stromal pattern of expression. Using antibody phage technology, we have generated a human monoclonal antibody (G11), with a dissociation constant KD = 4.2 nM for the human domain C. The G11 antibody, expressed in scFv and in mini-antibody (SIP) format, as well as a scFv-interleukin-2 fusion protein, was then characterized in quantitative biodistribution studies using mice grafted subcutaneously with U87 gliomas, revealing a selective tumor uptake, with tumor/blood ratios up to 11.8:1 at 24 h. A radioiodinated preparation of SIP(G11) was also investigated in a double tracer study using an orthotopic rat glioma model, confirming the antibody's ability to preferentially localize at the tumor site, with tumor/brain ratios superior to the ones observed with 18F-fluorodeoxyglucose. These tumor-targeting properties, together with the strong immunohistochemical staining of human tumor sections, indicate that the G11 antibody may be used as a portable targeting moiety for the selective delivery of imaging and therapeutic agents to gliomas and lung tumors.

Keywords: angiogenesis/antibody phage display/human monoclonal antibodies/tenascin-c/tumor targeting

Received June 30, 2006; accepted July 12, 2006.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 JNMHome page
T. von Lukowicz, M. Silacci, M. T. Wyss, E. Trachsel, C. Lohmann, A. Buck, T. F. Luscher, D. Neri, and C. M. Matter
Human Antibody Against C Domain of Tenascin-C Visualizes Murine Atherosclerotic Plaques Ex Vivo
J. Nucl. Med., April 1, 2007; 48(4): 582 - 587.
[Abstract] [Full Text] [PDF]


Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.